In early 2023, a 15-year-old female patient was diagnosed with an immature teratoma, a malignant germ cell tumor, located in her right ovary. Standard treatment was initiated, beginning with surgical resection of the tumor, followed by adjuvant chemotherapy. Unfortunately, despite aggressive management, the disease recurred and metastasized widely to the peritoneal cavity and liver, indicating a poor prognosis typically associated with widespread germ cell malignancies.
2023年初，一名15岁的女性患者被诊断出患有未成熟畸胎瘤，这是一种恶性生殖细胞肿瘤，位于她的右侧卵巢。经过标准治疗后，首先进行了肿瘤切除手术，随后进行了辅助化疗。不幸的是，尽管进行了积极的治疗，该疾病复发并广泛转移到腹膜腔和肝脏，这通常预示着与广泛性生殖细胞恶性肿瘤相关的不良预后。In April 2023, as part of an integrative approach to treatment, the patient began utilizing ECCT as Treatment of Recurrence Ovarian Immature Teratoma Cancer. ECCT is an emerging electric cancer therapy. ECCT is a non-invasive modality designed to disrupt cancer cell proliferation by applying low-frequency electric fields that target tumor cells while sparing normal tissue. The therapy was administered consistently over the next several months.
作为综合治疗方法的一部分，该患者于2023年4月开始使用ECCT（一种新兴的电癌治疗）。ECCT是一种非侵入性疗法，旨在通过应用低频电场来干扰癌细胞的增殖，靶向肿瘤细胞而不伤害正常组织。接下来的几个月中，该疗法持续应用。Throughout the course of ECCT, regular follow-ups and ultrasound imaging demonstrated gradual tumor shrinkage, with no significant adverse effects reported. The patient tolerated the therapy well, and the progression of her disease appeared to be arrested. Over the next 1.5 years, the combination of ECCT with previous surgical and chemotherapeutic interventions led to the patient finally achieving remission.
在ECCT治疗过程中，定期的随访和超声成像显示肿瘤逐渐缩小，且没有报告显著的不良反应。患者很好地耐受了该疗法，疾病的进展似乎得到了控制。在接下来的1.5年中，ECCT与之前的手术和化疗相结合，最终使患者达到了缓解状态。
Comments